These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 35284778)

  • 21. Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis.
    Hermans C; Ventriglia G; Obaji S; Beckermann BM; Lehle M; Catalani O; d'Oiron R; Frenzel L
    Res Pract Thromb Haemost; 2023 Nov; 7(8):102239. PubMed ID: 38193069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea.
    Lee H; Cho H; Han JW; Kim AY; Park S; Lee M; Cho S; Baik D; Kang HY
    Haemophilia; 2021 Jan; 27(1):e12-e21. PubMed ID: 32894895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.
    Shima M; Amano K; Ogawa Y; Yoneyama K; Ozaki R; Kobayashi R; Sakaida E; Saito M; Okamura T; Ito T; Hattori N; Higasa S; Suzuki N; Seki Y; Nogami K
    J Thromb Haemost; 2023 Mar; 21(3):534-545. PubMed ID: 36696195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors.
    Kempton C; Trask P; Parnes A; Niggli M; Campinha-Bacote A; U Callaghan M; O'Connell N; Paz-Priel I; Mahlangu JN
    Haemophilia; 2021 Mar; 27(2):221-228. PubMed ID: 33506955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.
    Tiede A; Hart C; Knöbl P; Greil R; Oldenburg J; Sachs UJ; Miesbach W; Pfrepper C; Trautmann-Grill K; Holstein K; Pilch J; Möhnle P; Schindler C; Weigt C; Schipp D; May M; Dobbelstein C; Pelzer FJ; Werwitzke S; Klamroth R
    Lancet Haematol; 2023 Nov; 10(11):e913-e921. PubMed ID: 37858328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Kasai R; Yoneyama K; Yoshida H; Nogami K
    Blood Adv; 2017 Oct; 1(22):1891-1899. PubMed ID: 29296836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review.
    Young G; Pipe SW; Kenet G; Oldenburg J; Safavi M; Czirok T; Nissen F; Mahlangu J
    Res Pract Thromb Haemost; 2024 May; 8(4):102415. PubMed ID: 38812987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.
    Shima M; Nogami K; Nagami S; Yoshida S; Yoneyama K; Ishiguro A; Suzuki T; Taki M
    Haemophilia; 2019 Nov; 25(6):979-987. PubMed ID: 31515851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A.
    Sun SX; Frick A; Balasa V; Roberts JC
    Expert Rev Hematol; 2022 Oct; 15(10):943-950. PubMed ID: 36000620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.
    Oldenburg J; Shima M; Kruse-Jarres R; Santagostino E; Mahlangu J; Lehle M; Selak Bienz N; Chebon S; Asikanius E; Trask P; Mancuso ME; Jiménez-Yuste V; von Mackensen S; Levy GG
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28474. PubMed ID: 32776489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.
    Batt K; Schultz BG; Caicedo J; Hollenbeak CS; Agrawal N; Chatterjee S; Bullano M
    Curr Med Res Opin; 2022 Oct; 38(10):1685-1693. PubMed ID: 35880468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emicizumab for the prevention of bleeds in hemophilia A.
    Mahlangu J
    Expert Opin Biol Ther; 2019 Aug; 19(8):753-761. PubMed ID: 31150297
    [No Abstract]   [Full Text] [Related]  

  • 34. Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII.
    Jonsson F; Schmitt C; Petry C; Mercier F; Frey N; Retout S
    Clin Pharmacokinet; 2021 Jul; 60(7):931-941. PubMed ID: 33709296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
    Skinner MW; Négrier C; Paz-Priel I; Chebon S; Jiménez-Yuste V; Callaghan MU; Lehle M; Niggli M; Mahlangu J; Shapiro A; Shima M; Campinha-Bacote A; Levy GG; Oldenburg J; von Mackensen S; Pipe SW
    Haemophilia; 2021 Sep; 27(5):854-865. PubMed ID: 34171159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies.
    Kruse-Jarres R; Peyvandi F; Oldenburg J; Chang T; Chebon S; Doral MY; Croteau SE; Lambert T; Kempton CL; Pipe SW; Ko RH; Trzaskoma B; Dhalluin C; Bienz NS; Niggli M; Lehle M; Paz-Priel I; Young G; Jiménez-Yuste V
    Blood Adv; 2022 Dec; 6(24):6140-6150. PubMed ID: 35939785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A.
    Shima M; Nagao A; Taki M; Matsushita T; Oshida K; Amano K; Nagami S; Okada N; Maisawa S; Nogami K
    Haemophilia; 2021 Jan; 27(1):81-89. PubMed ID: 33236410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
    Kiialainen A; Niggli M; Kempton CL; Castaman G; Chang T; Paz-Priel I; Adamkewicz JI; Levy GG
    Haemophilia; 2022 Nov; 28(6):1033-1043. PubMed ID: 35905294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.